Transition from epoprostenol to treprostinil in pulmonary arterial hypertension: a controlled trial

被引：0
|
作者：
Schilz, R.
Rubenfire, M.
Mclaughlin, V.
Allen, R.
Elliott, G.
Park, M.
Wade, M.
机构：
[1] Case Western Reserve Univ Hosp, Cleveland, OH 44106 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA
[4] LDS Hosp, Salt Lake City, UT USA
[5] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[6] United Therapeut Corp, Res Triangle Pk, NC USA
来源：
EUROPEAN HEART JOURNAL | 2006年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：622 / 622
页数：1
相关论文
共 50 条
  • [21] Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension
    Suleman, N
    Frost, AE
    CHEST, 2004, 126 (03) : 808 - 815
  • [22] Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension
    Verlinden, Nathan J.
    Walter, Claire
    Kanwar, Manreet
    Raina, Amresh
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (07) : 764 - 765
  • [23] TRANSITION FROM SELEXIPAG TO ORAL TREPROSTINIL IN A PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
    Patel, Amol
    Safdar, Zeenat
    CHEST, 2018, 154 (04) : 1023A - 1024A
  • [24] Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
    Oriaku, Ifeoma
    Patel, Amol
    Safdar, Zeenat
    PULMONARY CIRCULATION, 2020, 10 (01)
  • [25] Epoprostenol in pulmonary arterial hypertension
    Jacobs, Wouter
    Vonk-Noordegraaf, Anton
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (01) : 83 - 90
  • [26] Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension
    Preston, Ioana R.
    Feldman, Jeremy
    White, James
    Franco, Veronica
    Ishizawar, David
    Burger, Charles
    Waxman, Aaron B.
    Hill, Nicholas S.
    PULMONARY CIRCULATION, 2014, 4 (03) : 456 - 461
  • [27] Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series
    Fanous, Sherif M.
    Janmohamed, Munir
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (23) : 1877 - 1881
  • [28] Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
    Asuka Furukawa
    Yuichi Tamura
    Hiroya Iwahori
    Masato Goto
    Narutaka Ohashi
    Teruo Okabe
    Akio Kawamura
    BMC Pulmonary Medicine, 17
  • [29] Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
    Furukawa, Asuka
    Tamura, Yuichi
    Iwahori, Hiroya
    Goto, Masato
    Ohashi, Narutaka
    Okabe, Teruo
    Kawamura, Akio
    BMC PULMONARY MEDICINE, 2017, 17
  • [30] Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution
    Yanaka, Kenichi
    Guillien, Alicia
    Soumagne, Thibaud
    Benet, Justin
    Piliero, Nicolas
    Picard, Francois
    Pison, Christophe
    Sitbon, Olivier
    Bouvaist, Helene
    Degano, Bruno
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (06)
12345